Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hypofractionated Whole Breast Radiotherapy and Boost in Early-Stage Breast Cancer

Hypofractionated Whole Breast Radiotherapy and Boost in Early-Stage Breast Cancer Purpose of ReviewTo review postlumpectomy whole breast irradiation (WBI) in early-stage breast cancer with regard to the use of hypofractionation and a tumor bed boost.Recent FindingsHypofractionation is currently standard practice for most cases of postlumpectomy WBI. A boost is recommended for women at increased risk for local recurrence due to clinical or pathologic risk factors. A sequential boost is currently standard practice for WBI with either conventional or hypofractionated radiation. Phase I–II trials of hypofractionation and concurrent boost have shown comparably low risks for local recurrence and acute and late toxicity without adding additional treatment days to WBI.SummaryPostlumpectomy WBI with hypofractionation and concurrent boost is a promising method of gaining the local control benefit of a tumor bed boost but maintaining the shorter treatment length, lower cost, and convenience of hypofractionation. Phase III trials are pending that may make this approach more widely accepted practice. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Hypofractionated Whole Breast Radiotherapy and Boost in Early-Stage Breast Cancer

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/hypofractionated-whole-breast-radiotherapy-and-boost-in-early-stage-wta4escNcC
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00386-9
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewTo review postlumpectomy whole breast irradiation (WBI) in early-stage breast cancer with regard to the use of hypofractionation and a tumor bed boost.Recent FindingsHypofractionation is currently standard practice for most cases of postlumpectomy WBI. A boost is recommended for women at increased risk for local recurrence due to clinical or pathologic risk factors. A sequential boost is currently standard practice for WBI with either conventional or hypofractionated radiation. Phase I–II trials of hypofractionation and concurrent boost have shown comparably low risks for local recurrence and acute and late toxicity without adding additional treatment days to WBI.SummaryPostlumpectomy WBI with hypofractionation and concurrent boost is a promising method of gaining the local control benefit of a tumor bed boost but maintaining the shorter treatment length, lower cost, and convenience of hypofractionation. Phase III trials are pending that may make this approach more widely accepted practice.

Journal

Current Breast Cancer Reports – Springer Journals

Published: Oct 16, 2020

There are no references for this article.